Pyrazinetetracarboxamide: A Duplex Ligand for Palladium(II)

Tetraethylpyrazine-2,3,5,6-tetracarboxamide forms a dipalladium­(II) complex with acetates occupying the fourth coordination sites of the two bound metal ions. Crystallographic results indicate that the “duplex” dipincer has captured two protons that serve as the counterions. The protons lie between adjacent amide carbonyl groups with very short O···O distances of 2.435(5) Å. In the free base, the adjacent carbonyl groups are farther apart, averaging 3.196(3) Å. While the dipalladium­(II) complexes stack in an ordered stepwise fashion along the <i>a</i> axis, the free base molecules stack on top of each other, with each pincer rotated by about 60° from the one below

Discovery of 1‑(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)­pyrido[2,3‑<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against <i>BRAF</i> or <i>RAS</i> Mutant Tumor Cells

The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors. The kinase inhibitors vemurafenib and dabrafenib, which target oncogenic BRAF V600E, have shown significant clinical efficacy in melanoma patients harboring this mutation. Because of paradoxical pathway activation, both agents were demonstrated to promote growth and metastasis of tumor cells with <i>RAS</i> mutations in preclinical models and are contraindicated for treatment of cancer patients with <i>BRAF</i> WT background, including patients with <i>KRAS</i> or <i>NRAS</i> mutations. In order to eliminate the issues associated with paradoxical MAPK pathway activation and to provide therapeutic benefit to patients with <i>RAS</i> mutant cancers, we sought to identify a compound not only active against BRAF V600E but also wild type BRAF and CRAF. On the basis of its superior in vitro and in vivo profile, compound <b>13</b> was selected for further development and is currently being evaluated in phase I clinical studies